Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

Plain-language summary

Neuroinflammation plays a key role in Alzheimer's disease (AD), but the actions of microglial mediators may vary across stages of Aβ pathology. While drugs targeting brain immune responses are advancing to clinical trials, biomarkers to monitor their effects are lacking. This study investigated proteins expressed by activated microglia in three mouse models of Aβ pathology and α-synuclein, both during disease progression and after treatment, to evaluate their potential as in vivo biomarkers. Immunofluorescent staining was performed on cortical sections from App NL-G-F , tg-ArcSwe, and wild-type (WT) mice. TREM2, Axl, galectin-3, Aβ, and cytokines were measured by immunoassays in brain homogenates from WT, App NL-G-F , tg-ArcSwe, and tg-UppSwe mice across four age groups and from mice subjected to three treatment strategies targeting Aβ (beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor NB-360 and antibody RmAb158) or α-synuclein (antibody RmAb38E2). TREM2 and Axl colocalized with Iba1 and Aβ in App NL-G-F and tg-ArcSwe mice, with age-dependent increases observed in both models but not in tg-UppSwe. The lectin galectin-3 increased with age across all genotypes, including WT. Aβ correlated with elevated TREM2, Axl, and Galectin-3. Two months of BACE1-inhibition reduced TREM2, Axl, and galectin-3 in tg-ArcSwe mice and TREM2 and Axl in App NL-G-F mice. In summary, microglial TREM2, Axl, and galectin-3 are promising biomarkers for tracking AD-related neuroinflammation. Microglial interactions with Aβ likely influence the outcomes of Aβ-targeting therapies, and characterizing their dynamic states will inform the development of diagnostic tools and treatments relying on microglial activation to alleviate pathologies associated with neurodegenerative diseases. • TREM2, Axl, and Gal-3 increase with age and colocalize with amyloid plaques in mouse models of amyloid-beta pathology. • Different Aβ isoforms may drive the brain concentrations of inflammation proteins. • Type and length of treatment impact inflammation protein levels differently. • Extracellular TREM2, Axl, and galectin-3 are promising PET targets for monitoring Alzheimer-related microglial activation.

What this study adds

Evidence grade: Low

In three mouse models of Aβ pathology and α-synuclein, this study found that TREM2 and Axl colocalized with Iba1 and Aβ and increased with age, and that two months of BACE1 inhibition reduced TREM2, Axl and galectin-3 in tg-ArcSwe mice and TREM2 and Axl in App NL-G-F mice. The work evaluates these proteins as potential in vivo biomarkers for monitoring treatments targeting brain immune responses, but it is animal research and does not establish a treatment or cure for patients.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Dahlén, A. D., Roshanbin, S., Bucher, N. M., Sehlin, D., & Syvänen, S. (2025). Evaluating the impact of age and treatment on neuroinflammation-related proteins in mouse models of proteinopathies. Experimental Neurology. https://doi.org/10.1016/j.expneurol.2025.115475

Vancouver

Dahlén AD, Roshanbin S, Bucher NM, Sehlin D, Syvänen S. Evaluating the impact of age and treatment on neuroinflammation-related proteins in mouse models of proteinopathies. Experimental Neurology. 2025. doi:10.1016/j.expneurol.2025.115475. PMID: 40992617.

BibTeX

@article{dahlen2025-40992617,
  author  = {Dahlén, Amelia D. and Roshanbin, Sahar and Bucher, Nadja M and Sehlin, Dag and Syvänen, Stina},
  title   = {{Evaluating the impact of age and treatment on neuroinflammation-related proteins in mouse models of proteinopathies}},
  journal = {Experimental Neurology},
  year    = {2025},
  doi     = {10.1016/j.expneurol.2025.115475},
  pmid    = {40992617},
  url     = {https://doi.org/10.1016/j.expneurol.2025.115475}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In three mouse models of Aβ pathology and α-synuclein, this study found that TREM2 and Axl colocalized with Iba1 and Aβ and increased with age, and that two months of BACE1 inhibition reduced TREM2, Axl and galectin-3 in tg-ArcSwe mice and TREM2 and Axl in App NL-G-F mice. The work evaluates these proteins as potential in vivo biomarkers for monitoring treatments targeting brain immune responses, but it is animal research and does not establish a treatment or cure for patients.

Study details

How this study scored 34/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 34 of 100.34 of 100 points earned66 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Experimental Neurology)
Journal's citation record 3 / 4 Experimental Neurology: journal h-index 271 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Laboratory or animal study (title names “mouse”) — scores zero
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Stina Syvänen: h-index 36 (OpenAlex, whole career)
Institution's track record 1 / 3 Uppsala University: institution h-index 1,114 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40992617)
Free to read 2 / 2 Free to read
Total 34 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk genes beyond APOE from nearby years

Also in Risk genes beyond APOE

103 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →